A Systematic Review of Antiepilpetic Drug Initiation and Withdrawal
The Neurologist 15:122-131, Shih,J.J &Ochoa,J.G., 2009
Epilepsy
JNNP 57:264-277, Chadwick,D., 1994
Deprescribing in Epilepsy
JAMA Neurol 77:673-674, Terman, S.W.,et al, 2020
Efficacy and Tolerability of the new antiepileptic drugs II: Treatment-resistant epilepsy
Neurol 91:82-90, Kanner, A.M.,et al, 2018
Efficacy and Tolerability of the new antiepileptic drugs I: Treatment of new-onset epilepsy
Neurol 91:74-81, Kanner, A.M.,et al, 2018
Clinicopathologic Conference, Copper Deficiency Myelopathy
NEJM 377:1977-1984, Case 35-2017, 2017
Sexual Function in Men and Women With Neurological Disorders
Lancet 369:512-525, Rees,P.M.,et al, 2007
Adult Epilepsy
Lancet 367:1087-1100, Duncan,J.S.,et al, 2006
Carbamazepine Encephalopathy Masquerading as Creutzfeldt-Jakob Disease
Neurol 65:650-651, Horvath,J.,et al, 2005
Transient Lesion in the Splenium of the Corpus Callosum and Antiepileptic Drug Withdrawal
Neurol 65:1032-1036, Gurtler,S.,et al, 2005
Efficacy and Tolerability for the New Antiepileptic Drugs I: Treatment of New Onset Epilepsy
Neurol 62:1252-1260, French,J.A.,et al, 2004
Efficacy and Tolerability of the New Antiepleptic Drugs II: Treatment of Refractory Epilepsy
Neurol 62:1261-1273, French,J.A.,et al, 2004
Reversible Parkinsonism with Normal B-CIT-SPECT in Patients Exposed to Sodium Valproate
Neurol 62:1435-1437, Easterford,K.,et al, 2004
Practice Parameter: Treatment of the Child with a First Unprovoked Seizure
Neurol 60:166-175, Hirtz,D.,et al, 2003
Transient Lesion in the Splenium of the Corpus Callosum in an Epileptic Patient
Neurol 60:1838-1841, Mirsattari,S.M.,et al, 2003
Practice Patterns of Neurologists Regarding Bone and Mineral Effefcts of Antiepileptic Drug Therapy
Arch Neurol 58:1369-1374,1352, Valmadrid,C.,et al, 2001
Focal Lesion in the Splenium of the Corpus Callosum in Epileptic Patients:Antiepileptic Drug Toxicity
AJNR 20:125-129,131, Kim,S.S.,et al, 1999
Clumsiness, Confusion, Coma, and Valproate
Lancet 353:1408, Ellaway,C.J.,et al, 1999
Practice Advisory:The Use of Felbamate in the Treatment of Patients with Intractable Epilepsy, Report of the quality Standards Subcommittee of the AAN and the American Epilepsy Society
Neurol 52:1540-1545, French,J.,et al, 1999
Practice Parameter,Management Issues for Women with Epilepsy (Summary Statement)
Neurol 51:944-948, Rpt of the Quality Stnds Subcmte AAN, 1998
Reversible Dementia and Apparent Brain Atrophy During Valproate Therapy
Ann Neurol 38:687-691, Papazian,O.,et al, 1995
Valproic Acid-Induced Hyperammonemic Encephalopathy:MR Appearance
AJNR 15:1779-1781, Baganz,M.D.&Dross,P.E., 1994
Prolonged Absence Status epilepticus Assoc with Carbamazepine, Increased ICP & Trans MRI Abnor
Neurol 42:2198-2201, Callahan,D.J.&Noetzel,M.J., 1992
New-Onset Seizures Associated with Human Immunodeficiency Virus Infection: Causation and Clinical Features in 100 Cases
Am J Med 87:173-177, Holtzman, D.M.,et al, 1989
Phenytoin Neuropathy:Structural Changes in the Sural Nerve
Ann Neurol 19:162-167, Ramirez,J.A.,et al, 1986
Valproic Acid, Review of a New Antiepileptic Drug
Arch Neurol 36:393-398, Bruni,J.,et al, 1979